免责声明: 本站汇总 FDA、ClinicalTrials.gov、PubMed、SEC EDGAR 等官方公开数据,仅供一般参考,不构成医疗建议、诊断、治疗建议或投资建议。

FDA 510(k)

MTS 莱法米林 0.016- 256 µg/mL

K号: K200308 · 2020-04-06

决定日期2020-04-06
产品代码JWY
咨询委员会抱歉,您提供的内容“MI”不足以进行翻译。请提供完整的医疗设备监管文本,以便我能够进行准确的翻译。
决定实质等同

器械摘要

MTS Lefamulin 0.016- 256 µg/mL is the device name listed in this FDA 510(k) record. The listed applicant is Liofilchem S. R. 1.. It received FDA 510(k) clearance on 2020-04-06 under 510(k) number K200308. The device is classified under product code JWY. It was reviewed by the MI advisory panel. FDA Decision: Substantially Equivalent.

常见问题

What is the MTS Lefamulin 0.016- 256 µg/mL?

MTS Lefamulin 0.016- 256 µg/mL is a medical device that received FDA 510(k) clearance on 2020-04-06. The listed applicant is Liofilchem S. R. 1.. The 510(k) number is K200308.

When did MTS Lefamulin 0.016- 256 µg/mL receive FDA 510(k) clearance?

MTS Lefamulin 0.016- 256 µg/mL received FDA 510(k) clearance on 2020-04-06, under 510(k) number K200308.

Who is the listed applicant for MTS Lefamulin 0.016- 256 µg/mL?

The FDA 510(k) record lists Liofilchem S. R. 1. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for MTS Lefamulin 0.016- 256 µg/mL?

The FDA product code for MTS Lefamulin 0.016- 256 µg/mL is JWY.

相关临床试验

关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系;请查阅链接的官方来源。

相关器械(代码:JWY)

关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系;请查阅链接的官方来源。

官方来源

在 FDA 数据库中查看 →

数据来源于FDA开放API。如需最新且权威的信息,请务必参考官方记录。

↑